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Letters to the Editor
Switching Thienopyridines:
Hypothetical Versus Real Risks
I enjoyed reading the quality paper by Campo et al. (1) that tried
to determine whether platelet response after thienopyridines is
drug or class specific in a broad spectrum of post-stent patients.
The team should be acknowledged for the effort and for realistic
rates for low response after clopidogrel (21%), and ticlopidine
(19%). The major take-home message conveyed to the readership
is that clopidogrel-treated patients may be switched to ticlopidine
if “resistance” is determined by the platelet tests. However, the
practical implications of this idea are not obvious, may be danger-
ous, may not be supported by clinical or epidemiologic evidence,
and deserve at least some clarification and/or adjustment.
In fact, low response to clopidogrel as a major risk factor for the
worsened vascular outcomes has been suspected but never proven
to be a real clinical phenomena, especially considering that no load
75 mg clopidogrel saved 119 lives, and provided an absolute
mortality benefit after myocardial infarction in COMMIT
(Clopidogrel and Metoprolol in Myocardial Infarction Trial)
( 2 ). Also, none of the small observation studies monitor
compliance by measuring clopidogrel metabolites in plasma.
Therefore, “clopidogrel resistance” is a laboratory finding,
rather than a clinically relevant hazard unless further random-
ized evidence became available (3 ).
On the other hand, substituting clopidogrel with ticlopidine
definitely increases the bone marrow toxicity risks. Indeed, neu-
tropenia and thrombocytopenia were 2-fold higher in the ticlopi-
dine arm than in patients treated with clopidogrel in CLASSICS
(Clopidogrel Aspirin Stent International Cooperative Study) (4).
Doubled cytotoxicity rates after ticlopidine were confirmed in a
post-stent study (5) and a recent meta-analysis of 11,668 patients
(6). Therefore, the suggestion that in case of low platelet response
after clopidogrel patients should be switched to ticlopidine is not valid.
Unless there is proof that response after clopidogrel is indeed linked to
the clinical outcomes, monitoring compliance and potential tailoring
of dual antiplatelet regimens with aspirin and clopidogrel will be a
safer alternative than switching thienopyridines.
*Victor L. Serebruany
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Johns Hopkins University
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Towson, Maryland 21204
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Reply
We welcome the thoughtful comments by Dr. Serebruany to our
recent publication on clopidogrel poor responsiveness in a broad
population undergoing coronary stenting (1). Our major focus was
to assess whether clopidogrel poor responders display inadequate
platelet inhibition also after ticlopidine administration. We found
that the great majority (83%) of patients who were clopidogrel
nonresponders became responsive to ticlopidine, reaching a higher
level of platelet inhibition (platelet aggregation [PA] 69  15 vs.
44  18; p  0.01).
On the other hand, 23 patients who were responsive to
clopidogrel showed resistance to ticlopidine and correspondingly
less platelet inhibition with this drug (PA 46  15 vs. 70  15;
p  0.01).
When taken together our findings strongly suggest that poor
responsiveness to currently commercially available thienopyridines
may frequently be a drug-specific more than a class-effect mech-
anism. This conclusion holds particularly true in consideration that
in the currently recommended regimen ticlopidine at steady state
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does not differ in terms of average inhibition of platelet aggrega-
tion than clopidogrel. This again emphasizes that individual drug
response more than average potency of the 2 tested drugs explain
our findings. In keeping with our findings, only a minority (15%)
of poor responders to clopidogrel displayed a normal response to the
same drug after doubling the dose in a recent phase II study ( 2).
We strongly disagree that “The major take-home message
conveyed to the readership is that clopidogrel-treated patients may
be switched to ticlopidine if ‘resistance’ is determined by the
platelet tests.” Indeed, in keeping with the conclusion statement of
our recent paper, our findings, especially in the current pre-
prasugrel era, should affect the design of future trials rather than
clinical practice. The observation that ticlopidine, at the currently
recommended dosage, unlike clopidogrel at double regimen, over-
comes resistance to clopidogrel in the great majority of cases may
prompt randomized controlled studies where standard care after
stenting (i.e., clopidogrel 75 mg/day) is compared with tailored
antiplatelet treatment (clopidogrel 150 mg/day in nonresponders
to clopidogrel standard regimen or ticlopidine in nonresponders to
clopidogrel double dose). Until such a study becomes available,
both the risks and benefits of tailoring treatment based on target
platelet inhibition will remain hypothetical.
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Relationship Between Atrial
Fibrillation and Left Atrial Size
The paper by Bangalore et al. (1) in a recent issue of the Journal
evaluated the role of diastolic dysfunction as measured by left atrial
(LA) size and the associated risk for adverse cardiovascular events
in patients undergoing stress echocardiography. The authors report
indexed LA size as a predictor of cardiac events independent of
traditional clinical risk factors. Patients with significant mitral
valve disease and with significant left ventricular systolic dysfunc-
tion were appropriately excluded from this study. However, atrial
fibrillation (AF) is another important potential confounder, be-
cause is it known to affect LA remodeling and geometry ( 2) and is
a known risk factor for cardiovascular events, particularly stroke.
This remodeling effect is independent of loading conditions within
the LA and can occur in both chronic and paroxysmal AF (3). It
would be important to know whether AF was included in the
multivariate analysis as well as the percent of patients who carried
the diagnosis of AF. Furthermore, if LA size could predict
prognosis in the subgroup of patients without AF to a similar
extent as that reported in this study, this would lend further
validity to the authors’ argument to incorporate LA size into the
prognostic interpretation of stress testing.
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Reply
We agree with the comment of Dr. Goldberg about the relation-
ships between atrial fibrillation (AF) and left atrial (LA) size. In
the AFFIRM (Atrial Fibrillation Follow-up Investigation of
Rhythm Management) study of 4,060 patients with AF only 33%
of patients had a normal LA size (1). Patients with dilated left
atrium are more prone to AF, and patients with AF and a dilated
left atrium are more likely to remain in AF than those with normal
LA dimensions. Atrial fibrillation is also known to affect LA
remodeling and geometry. In a prospective echocardiographic
follow-up of patients with AF, atrial enlargement was shown to
occur as a consequence of AF (2). Regardless of whether LA
enlargement is a cause for or a consequence of AF, the prognosis
is worse compared with patients with a normal LA size.
In our study cohort of 2,705 patients undergoing stress
echocardiography (3), only 63 (2.3%) patients had either AF or
atrial flutter. Analysis performed after excluding this cohort
showed that LA size was able to further risk stratify patients
undergoing stress echocardiography (Fig. 1). The results were
similar for the multivariable analysis and incremental prognostic
value analysis. Thus even after excluding patients with AF/atrial
flutter, LA size provided independent and incremental value
over standard risk factors, including left ventricular systolic
dysfunction and ischemia, and was a powerful prognosticator.
Therefore, it should be routinely used in the prognostic inter-
pretation of stress echocardiography.
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